Ashkon Software



ADXS - Advaxis, Inc.

Advaxis, Inc. logo Advaxis is primarily focused on the development of immunotherapy products that utilize its proprietary Listeria monocytogenes (Lm) platform to stimulate the immune system to target and destroy cancer cells. The company's lead product candidate is axalimogene filolisbac (AXAL), which is being developed for the treatment of several types of cancer, including cervical, head and neck, and anal cancer.

In addition to AXAL, Advaxis has a pipeline of other Lm-based immunotherapy products in development, including ADXS-HOT, which targets cancers associated with human papillomavirus (HPV), and ADXS-504, which targets prostate cancer.

The company has reported financial results for the third quarter of 2021, reporting a net loss of $6.9 million, compared to a net loss of $6.4 million in the same period in the previous year. Advaxis reported cash and cash equivalents of $31.4 million as of September 30, 2021.

Advaxis has been focused on advancing its pipeline of immunotherapy products and entering into partnerships and collaborations with other companies. In November 2021, the company announced that it had entered into a clinical collaboration with Merck to evaluate the safety and efficacy of a combination therapy of AXAL and Merck's anti-PD-1 therapy for the treatment of cervical cancer.

However, the company's financial performance and operations may be impacted by various factors, including the outcome of clinical trials, regulatory changes, and competition in the biotechnology industry. In addition, the success of immunotherapy products may be affected by factors such as the ability of the immune system to respond to treatment and the presence of tumors with resistance to therapy.

Overall, Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products for the treatment of cancer. The company has a pipeline of Lm-based immunotherapy products in development and has entered into partnerships and collaborations to advance its research and development efforts. However, the company's financial performance and operations are subject to various risks and uncertainties associated with the biotechnology industry and the success of immunotherap




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer